How Much Does It Cost to Open a Medical Weight Loss Clinic in 2026?

A Startup Investment Breakdown Built on Current Sourcing Economics, Not 2024 Assumptions

Why Many Budgets for This Clinic Type Are Now Wrong

Startup budgets circulating for medical weight loss clinics were largely built during the compounding era, before the FDA declared the semaglutide and tirzepatide shortages resolved and routine compounding of copies ended. Those numbers no longer describe the business.

ACG's planning estimate for the startup investment in a medical weight loss clinic is about $107,000 to $130,000, our consulting fee included, the same range we use for each of the 13 clinic types we support; working capital sits above it. A budget built on compounding-era sourcing will misstate the working capital a clinic needs above that range. Pricing for our engagement itself is discussed once the scope is clear. The categories below reflect current conditions.

For the full business model context, see The Metabolic Weight Loss Clinic Business Opportunity. For how our team helps founders launch one, see what it takes to open a medical weight loss clinic.

Legal Structure and Entity Formation

The MSO structure that lets a non-physician own the business side must be drafted by healthcare counsel in the clinic's state. For a weight loss clinic, the Management Services Agreement should account for prescribing arrangements and, if the clinic intends to pursue an investigational study pathway, the research site structure that sits alongside it.

Healthcare counsel's fees vary with the state's complexity. Clinics planning the IRB route should budget legal review of the research arrangement separately.

Medical Director and Prescribing Infrastructure

Medical director compensation for a weight loss clinic varies by state and scope. The scope matters more here than in some clinic types, because GLP-1 prescribing under current rules places documentation burden squarely on the prescribing provider, and a medical director who treats the role as a signature is a genuine liability in this category.

Budget the first months of compensation as startup capital, since it accrues before meaningful patient revenue.

The IRB Pathway, If You Are Pursuing It

Beyond FDA-approved product and narrow patient-specific compounding, compounded semaglutide and tirzepatide require an FDA-regulated clinical study run under an IRB-approved protocol and an investigational new drug application (IND). ACG helps clients prepare both the IRB application and the IND. A study drug cannot be promoted or sold commercially, and charging participants for it requires FDA's written authorization and is limited to direct cost. A clinic that runs such a study budgets it as a discrete startup category. Compounding narrowed sharply once the FDA declared the shortages of semaglutide and tirzepatide resolved (see its policies for compounders as GLP-1 supply began to stabilize); what remains is narrow.

•IRB review fees, which depend on the board and the number of locations

•ACG's help preparing the IRB application and the IND, with pricing discussed once the scope is clear

•Contingency for the possibility of denial or substantial protocol revision: approval is not guaranteed, and the budget should not assume it

Clinics should also account for the ongoing operational cost of research conduct after approval, including documentation time and continuing review obligations.

Body Composition and Clinical Equipment

This is the equipment category that separates a metabolic health clinic from a prescription mill, and it is frequently underbudgeted.

A clinical-grade body composition analyzer (a bioelectrical impedance system suitable for clinical use) is a capital purchase whose price depends on capability. Some clinics instead partner for DEXA access, which shifts the cost to a per-scan basis. Either approach provides what scale weight cannot: the fat mass versus lean mass distinction that determines whether a patient's weight loss is actually a good clinical outcome.

In-office phlebotomy capability (a draw chair, a centrifuge, refrigeration and supply inventory) can support monitoring compliance and specimen control.

Initial Product Inventory

This line varies with the sourcing path. A commercial program runs on FDA-approved product bought through authorized distributors (Wegovy and Zepbound are approved for chronic weight management), so model inventory at those prices. A study drug cannot be sold commercially, and FDA does not accept a lower price as a reason to compound a copy of a commercially available drug, so neither belongs in the inventory budget as a cheaper alternative.

Rather than a single figure, model this as a per-patient monthly cost against your specific sourcing arrangement, then multiply by the patient volume you expect in months one through three. A clinic that budgets inventory as a fixed startup number and then discovers its actual sourcing cost is well above the assumption has a working capital problem, not an inventory problem.

Technology, Space, and Launch Marketing

A HIPAA-compliant EMR configured for longitudinal metabolic tracking and prescription documentation is a first-year setup cost. A weight loss clinic needs consultation and assessment rooms, and first and last month plus a deposit on the space come before opening. So does the pre-launch marketing designed to fill the opening consultation schedule, on a strategy ACG plans with you; marketing execution is a separate engagement.

The Total Investment Picture

ACG's planning estimate for the startup investment in a medical weight loss clinic, as for any of the 13 clinic types we support, is about $107,000 to $130,000, our consulting fee included. Where a clinic lands in that range depends on the state, the market, the lease and the equipment it buys; a clinic running an IRB study budgets that work separately. Pricing for our engagement itself is discussed once the scope is clear; see our five-phase clinic launch. Entrepreneurs organizing this across one-time and recurring categories can use the SBA's startup cost planning framework, though the healthcare-specific compliance items above will not appear in any general small business template.

Working capital sits above the startup investment and should cover the months of fixed operating costs before patient revenue covers them.

Staffing the Clinic

A medical weight loss clinic needs, at minimum, a prescribing clinician, a clinical staff member capable of running body composition assessments and lab draws, and a patient coordinator managing intake and the consultation-to-enrollment conversation.

One of the roles most often underestimated is the coordinator. GLP-1 patients arrive with more prior research and more price sensitivity than many cash-pay health patients, and the consultation frequently involves explaining why the clinic's sourcing and monitoring approach differs from a telehealth alternative they have already priced. A coordinator who can hold that conversation credibly can convert better than one reading from a script. A founder who would rather open a virtual practice staffs it differently, with prescribers licensed in each patient's state, and can plan that with an ACG telehealth consultant.

Budget the first months of staffing as startup capital alongside medical director compensation, since payroll begins before the patient panel is built.

What the Breakeven Math Actually Looks Like

Fixed monthly operating costs for a clinic of this type cover rent, medical director, clinical and administrative staffing, technology, and baseline marketing.

Revenue per patient depends heavily on program structure. A prescription-only program earns a management fee around the medication; a comprehensive metabolic program with biomarker panels, body composition tracking, and hormone assessment where indicated, on the schedule the medical director sets, can earn more per patient per month and can retain patients longer.

The practical consequence is that breakeven patient count varies widely by model. A clinic running a thin prescription-only program needs substantially more patients to cover the same fixed costs than a clinic running a comprehensive program. This is the clearest financial argument for the diversified service model, and it is why the service design belongs in the budget from the start.

Actual results depend on market conditions, sourcing arrangement, pricing, retention, and execution.

To work through the investment picture for your market and sourcing strategy with our team, book a free 30-minute strategy call.

Frequently Asked Questions

How does sourcing choice affect the startup budget?

Substantially. Product cost per patient per month is one of the largest variables in the model. A commercial program budgets FDA-approved product at the price its authorized distributor confirms; neither a study drug nor a compounded copy belongs in the budget as a cheaper alternative. Build the budget against a specific, confirmed sourcing arrangement rather than a category average, and confirm pricing in writing before finalizing working capital requirements.

Is a body composition analyzer necessary or optional?

Clinically it is close to necessary for a practice positioning itself as metabolic health rather than weight loss, though how it is used is the medical director's call. GLP-1 therapy reduces lean mass as well as fat (the STEP 1 trial of semaglutide showed decreases in total fat mass and total lean body mass), and a clinic that cannot measure the distinction cannot manage it. Commercially, it is also the clearest differentiator against telehealth prescription services.

Should a new clinic pursue the IRB pathway from the start?

Only if genuinely prepared to operate as a research site with the documentation and continuing review obligations that entails. It adds IRB review fees and the preparation of the IRB application and the IND to the startup budget, and it carries approval uncertainty. Many clinics launch on FDA-approved branded product and a broader metabolic service menu first, then evaluate the study pathway once operations are stable.

How does this compare to opening a hormone or longevity clinic?

ACG's planning estimate for the startup investment is the same for all three: about $107,000 to $130,000, our consulting fee included, with working capital above it. What differs is where the money goes: here, body composition equipment and the product inventory line, which varies more in this category than in many others. Pricing for our engagement itself is discussed once the scope is clear.